Background: Although chemotherapy is used routinely in pediatric medulloblastoma (MB) patients, its benefit for adult MB is unclear. We evaluated the survival impact of adjuvant chemotherapy in adult MB. Methods: Using the National Cancer Data Base, we identified patients aged 18 years and older who were diagnosed with MB in 2004-2012 and underwent surgical resection and adjuvant craniospinal irradiation (CSI). Patients were divided into those who received adjuvant CSI and chemotherapy (CRT) or CSI alone (RT). Predictors of CRT compared with RT were evaluated with univariable and multivariable logistic regression. Survival analysis was limited to patients receiving CSI doses between 23 and 36 Gy. Overall survival (OS) was evaluated using the Kaplan-Meier estimator, log-rank test, multivariable Cox proportional hazards modeling, and propensity score matching. Results: Of the 751 patients included, 520 (69.2%) received CRT, and 231 (30.8%) received RT. With median follow-up of 5.0 years, estimated 5-year OS was superior in patients receiving CRT versus RT (86.1% vs 71.6%, P < .0001). On multivariable analysis, after controlling for risk factors, CRT was associated with superior OS compared with RT (HR: 0.53; 95%CI: 0.32-0.88, P = .01). On planned subgroup analyses, the 5 year OS of patients receiving CRT versus RT was improved for M0 patients (P < .0001), for patients receiving 36 Gy CSI (P = .0007), and for M0 patients receiving 36 Gy CSI (P = .0008). Conclusions: This national database analysis demonstrates that combined postoperative chemotherapy and radiotherapy are associated with superior survival for adult MB compared with radiotherapy alone, even for M0 patients who receive high-dose CSI.
Background: Although chemotherapy is used routinely in pediatric medulloblastoma (MB) patients, its benefit for adult MB is unclear. We evaluated the survival impact of adjuvant chemotherapy in adult MB. Methods: Using the National Cancer Data Base, we identified patients aged 18 years and older who were diagnosed with MB in 2004-2012 and underwent surgical resection and adjuvant craniospinal irradiation (CSI). Patients were divided into those who received adjuvant CSI and chemotherapy (CRT) or CSI alone (RT). Predictors of CRT compared with RT were evaluated with univariable and multivariable logistic regression. Survival analysis was limited to patients receiving CSI doses between 23 and 36 Gy. Overall survival (OS) was evaluated using the Kaplan-Meier estimator, log-rank test, multivariable Cox proportional hazards modeling, and propensity score matching. Results: Of the 751 patients included, 520 (69.2%) received CRT, and 231 (30.8%) received RT. With median follow-up of 5.0 years, estimated 5-year OS was superior in patients receiving CRT versus RT (86.1% vs 71.6%, P < .0001). On multivariable analysis, after controlling for risk factors, CRT was associated with superior OS compared with RT (HR: 0.53; 95%CI: 0.32-0.88, P = .01). On planned subgroup analyses, the 5 year OS of patients receiving CRT versus RT was improved for M0 patients (P < .0001), for patients receiving 36 Gy CSI (P = .0007), and for M0 patients receiving 36 Gy CSI (P = .0008). Conclusions: This national database analysis demonstrates that combined postoperative chemotherapy and radiotherapy are associated with superior survival for adult MB compared with radiotherapy alone, even for M0 patients who receive high-dose CSI.
Authors: Thomas E Merchant; Larry E Kun; Matthew J Krasin; Dana Wallace; Murali M Chintagumpala; Shiao Y Woo; David M Ashley; Maree Sexton; Stewart J Kellie; Verity Ahern; Amar Gajjar Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-24 Impact factor: 7.038
Authors: P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: James G Douglas; Jerry L Barker; Richard G Ellenbogen; J Russell Geyer Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: C Carrie; C Lasset; C Alapetite; C Haie-Meder; S Hoffstetter; M C Demaille; C Kerr; J P Wagner; J L Lagrange; J P Maire Journal: Cancer Date: 1994-10-15 Impact factor: 6.860
Authors: Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy Journal: J Neurooncol Date: 2018-05-23 Impact factor: 4.130
Authors: Marta Penas-Prado; Brett J Theeler; Brittany Cordeiro; Ira J Dunkel; Peter Hau; Anita Mahajan; Giles W Robinson; Nicole Willmarth; Orwa Aboud; Kenneth Aldape; John A Butman; Amar Gajjar; William Kelly; Ganesh Rao; Margarita Raygada; Christine Siegel; Carlos G Romo; Terri S Armstrong; Mark R Gilbert Journal: Neurooncol Adv Date: 2020-08-17
Authors: Paul A Northcott; Andrey Korshunov; Vijay Ramaswamy; Hallie Coltin; Lakshmikirupa Sundaresan; Kyle S Smith; Patryk Skowron; Luca Massimi; Charles G Eberhart; Karisa C Schreck; Nalin Gupta; William A Weiss; Daniela Tirapelli; Carlos Carlotti; Kay K W Li; Marina Ryzhova; Andrey Golanov; Olga Zheludkova; Oksana Absalyamova; Konstantin Okonechnikov; Damian Stichel; Andreas von Deimling; Caterina Giannini; Scott Raskin; Erwin G Van Meir; Jennifer A Chan; Daniel Fults; Lola B Chambless; Seung-Ki Kim; Alexandre Vasiljevic; Cecile Faure-Conter; Rajeev Vibhakar; Shin Jung; Sarah Leary; Jaume Mora; Roger E McLendon; Ian F Pollack; Peter Hauser; Wieslawa A Grajkowska; Joshua B Rubin; Marie-Lise C van Veelen; Pim J French; Johan M Kros; Linda M Liau; Stefan M Pfister; Marcel Kool; Noriyuki Kijima; Michael D Taylor; Roger J Packer Journal: Acta Neuropathol Date: 2021-08-18 Impact factor: 15.887
Authors: Paola Gaviani; Giorgia Simonetti; Roberta Rudà; Federica Franchino; Giuseppe Lombardi; Marco Possanzini; Sara Squintu; Veronica Villani; Mariaausilia Teriaca; Francesco Cavallieri; Maria Caffo; Andrea Salmaggi; Andrea Bianco; Elena Anghileri; Mariangela Farinotti; Irene Tramacere; Antonio Silvani Journal: Neurol Sci Date: 2020-07-11 Impact factor: 3.307
Authors: Brian De; Kathryn Beal; Kevin C De Braganca; Mark M Souweidane; Ira J Dunkel; Yasmin Khakoo; Stephen W Gilheeney; Lisa M DeAngelis; Paul Menzel; Suchit H Patel; Suzanne L Wolden Journal: J Neurooncol Date: 2017-10-10 Impact factor: 4.130
Authors: Roshan S Prabhu; Christopher D Corso; Matthew C Ward; John H Heinzerling; Reshika Dhakal; Zachary S Buchwald; Kirtesh R Patel; Anthony L Asher; Ashley L Sumrall; Stuart H Burri Journal: Neurooncol Pract Date: 2019-12-19
Authors: I-Chia Liu; Adam L Holtzman; Ronny L Rotondo; Daniel J Indelicato; Sridharan Gururangan; Robert Cavaliere; Bridgette Carter; Christopher G Morris; Daryoush Tavanaiepour; Michael S Rutenberg Journal: J Neurooncol Date: 2021-06-08 Impact factor: 4.130